Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:7/28/2018
Start Date:July 10, 2018
End Date:December 2019
Contact:Kimberly Vanover, PhD
Email:itciclinicaltrials@intracellulartherapies.com
Phone:646-440-9333

Use our guide to learn which trials are right for you!

Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure

This is a Phase I/II randomized, double-blind, placebo-controlled, single rising dose study
in patients with systolic heart failure to evaluate the safety and tolerability of ITI-214.


Inclusion Criteria:

- NYHA class II-III heart failure

- Ejection fraction equal to or below 35%

- On stable heart failure drug treatment

Exclusion Criteria:

- Considered medically inappropriate for study participation
We found this trial at
2
sites
Durham, North Carolina 27715
?
mi
from
Durham, NC
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Nisha Gilotra, MD
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials